This year’s American Society of Hematology (ASH) 2018 Annual Meeting was held on December 1-4 in San Diego, California. Physicians, researchers, and health care professionals learned about the latest advances in the treatment of blood cancers and blood disorders. The meeting featured more than 4,400 abstracts, including over 1,000 presented at oral sessions. Many of the reported trials are expected to have an impact on clinical practice.
CheckRare was in attendance and provides some of the conference highlights, focusing on rare diseases.
Sickle Cell Disease: Overview and Emerging Stem Cell Transplant Therapy
Hemophilia: Updated Positive Interim Data from Phase 2/3 Study of Marzeptacog Alfa
Myelodysplastic Syndromes Overview and Personalized Prediction Model for Patients
iPATH Study: Key Biomarkers That Affect Bleeding Patterns, Response to Treatment for Hemophilia A
Hereditary TTR Amyloidosis and the NEURO-TTR Study
Venclexta Data Positive for AML
New Treatment Option for Primary Hemophagocytic Lymphohistiocytosis
Management of Hematologic Diseases With Cellular and Immunotherapies
Checkmate 436: Two-Drug Combo Shows Promise for Primary Mediastinal Large B-cell Lymphoma
